DAFTAR PUSTAKA

[1] C. Maaß, J. P. Sachs, D. Hardiansyah, F. M. Mottaghy, P. Kletting, and G. Glatting, "Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule," *EJNMMI Res.*, vol. 6, no. 1, pp. 1–9, 2016.

[2] W. E. Bolch, K. F. Eckerman, G. Sgouros, and S. R. Thomas, "MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry—standardization of nomenclature," *J. Nucl. Med.*, vol. 50, no. 3, pp. 477–484, 2009.

[3] D. Hardiansyah *et al.*, "The role of patient-based treatment planning in peptide receptor radionuclide therapy," *Eur. J. Nucl. Med. Mol. Imaging*, vol. 43, no. 5, pp. 871–880, 2016.

[4] A. R. Haug, "PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?," *EJNMMI Res.*, vol. 10, no. 1, pp. 1–3, 2020.

[5] J. A. Siegel *et al.*, "MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates," *J. Nucl. Med.*, vol. 40, no. 2, pp. 37S-61S, 1999.

[6] H. Hänscheid, C. Lapa, A. K. Buck, M. Lassmann, and R. A. Werner, "Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days," *J. Nucl. Med.*, vol. 59, no. 1, pp. 75–81, 2018.

[7] M. Miederer, H. Reber, A. Helisch, C. Fottner, M. Weber, and M. Schreckenberger, "One single-time-point kidney uptake from OctreoScan correlates with number of desintegrations measured over 72 hours and calculated for the 6.7 hours half-life nuclide 177Lu," *Clin. Nucl. Med.*, vol. 37,

no. 10, pp. e245–e248, 2012.

[8] J. Gustafsson and J. Taprogge, “Theoretical aspects on the use of single-time-point dosimetry for radionuclide therapy,” *Phys. Med. Biol.*, vol. 67, no. 2, p. 25003, 2022.

[9] X. Hou *et al.*, “Feasibility of single-time-point dosimetry for radiopharmaceutical therapies,” *J. Nucl. Med.*, vol. 62, no. 7, pp. 1006–1011, 2021.

[10] J. I. Gear *et al.*, “EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations,” *Eur. J. Nucl. Med. Mol. Imaging*, vol. 45, no. 13, pp. 2456–2474, 2018.

[11] G. Glatting, P. Kletting, S. N. Reske, K. Hohl, and C. Ring, “Choosing the optimal fit function: Comparison of the Akaike information criterion and the F-test,” *Med. Phys.*, vol. 34, no. 11, pp. 4285–4292, 2007, doi: 10.1118/1.2794176.

[12] M. Gotthardt *et al.*, “Indication for different mechanisms of kidney uptake of radiolabeled peptides,” *J. Nucl. Med.*, vol. 48, no. 4, pp. 596–601, 2007.

[13] J. Thundimadathil, “Cancer treatment using peptides: current therapies and future prospects,” *J. Amino Acids*, vol. 2012, 2012.

[14] S. R. Cherry, J. A. Sorenson, and M. E. Phelps, *Physics in nuclear medicine e-Book*. Elsevier Health Sciences, 2012.

[15] G. Glatting, M. Bardiès, and M. Lassmann, “Treatment planning in molecular radiotherapy,” *Z. Med. Phys.*, vol. 23, no. 4, pp. 262–269, 2013.

[16] P. Vicini, A. B. Brill, M. G. Stabin, and A. Rescigno, “Kinetic modeling in support of radionuclide dose assessment,” in *Seminars in nuclear medicine*, 2008, vol. 38, no. 5, pp. 335–346.

[17] L. D. Marinelli, J. B. Trunnell, R. F. Hill, and F. W. Foote, “Factors Involved

in the Experimental Therapy of Metastatic Thyroid Cancer with I131: A Preliminary Report," *Radiology*, vol. 51, no. 4, pp. 553–557, 1948.

[18] L. D. Jiménez-Franco, G. Glatting, V. Prasad, W. A. Weber, A. J. Beer, and P. Kletting, "Effect of tumor perfusion and receptor density on tumor control probability in 177Lu-DOTATATE therapy: An in silico analysis for standard and optimized treatment," *J. Nucl. Med.*, vol. 62, no. 1, pp. 92–98, 2021, doi: 10.2967/jnumed.120.245068.

[19] As. Kopp, "INDEX OF WORLD PHARMACOPOEIAS and PHARMACOPOEIAL AUTHORITIES The Index of World Pharmacopoeias and Pharmacopoeial Authorities has been circulated to national and regional Table of contents," no. May, 2019.

[20] R. R. ISLAMIATY and E. L. I. HALIMAH, "Tinjauan Pustaka Mengenai Karakteristik Radioisotop yang Digunakan pada Pembuatan Radiofarmaka," *Farmaka*, vol. 16, no. 1, pp. 222–230, 2018.

[21] F. A. Mettler and M. J. Guiberteau, *Essentials of Nuclear Medicine and Molecular Imaging E-Book*. Elsevier Health Sciences, 2018.

[22] T. U. S. Food and T. U. S. Food, "FDA approves new treatment for certain digestive tract cancers | FDA," pp. 2–3, 2018, [Online]. Available: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-certain-digestive-tract-cancers.

[23] B. L. R. Kam *et al.*, "Lutetium-labelled peptides for therapy of neuroendocrine tumours," *Eur. J. Nucl. Med. Mol. Imaging*, vol. 39, no. 1, pp. 103–112, 2012.

[24] J.-P. Esser *et al.*, "Comparison of [177Lu-DOTA0, Tyr3] octreotate and [177Lu-DOTA0, Tyr3] octreotide: which peptide is preferable for PRRT?," *Eur. J. Nucl. Med. Mol. Imaging*, vol. 33, no. 11, pp. 1346–1351, 2006.

[25] P. Kletting *et al.*, "Molecular radiotherapy: the NUKFIT software for

calculating the time-integrated activity coefficient," *Med. Phys.*, vol. 40, no. 10, p. 102504, 2013.

[26] M. E. Glickman and D. A. van Dyk, "Basic bayesian methods," *Top. Biostat.*, pp. 319–338, 2007.

[27] P. Kletting and G. Glatting, "Model selection for time-activity curves: The corrected Akaike," *Z. Med. Phys.*, vol. 19, no. 3, pp. 200–206, 2009.

[28] T. P. Devasia, Y. K. Dewaraja, K. A. Frey, K. K. Wong, and M. J. Schipper, "A Novel Time-Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE," *J. Nucl. Med.*, vol. 62, no. 8, pp. 1118–1125, 2021, doi: 10.2967/jnumed.120.256255.

[29] "Pembuatan Radioisotop Lutesium." .

[30] D. Hardiansyah, A. Riana, A. J. Beer, and G. Glatting, "Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model," *Zeitschrift fuer Medizinische Phys.*, 2022, doi: 10.1016/j.zemedi.2022.06.004.